Phase I-II

A Phase I, multicenter, open-label, adaptive design, dose-escalation study of KK8123 in adult patients with X-linked hypophosphatemia

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this research study is to determine the safety and effectiveness of a new treatment for adults with XLH. The study medication is called KK8123 and is expected to help improve blood phosphorus levels and thereby improve the symptoms of XLH.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Olear

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Clemens Bergwitz, MD
Associate Professor of Medicine (Endocrinology)

Sub-Investigator

Clemens Bergwitz, MD

Last Updated
02/26/2025
Study HIC
#2000037697